Bo Lagerqvist.

A total of 15 additional patients in Sweden and Iceland had been identified who had been potentially eligible for inclusion but hadn’t undergone randomization in the Flavor study. Clinical End Points The rate of death from any cause at 1 year was 5.3 percent in the thrombus-aspiration group, as compared with 5.6 percent in the PCI-only group ; the results were identical for the interval from day time 31 to day 365 . The rate of rehospitalization for myocardial infarction at 12 months was 2.7 percent and 2.7 percent in the two groups, respectively , and the rate of stent thrombosis was 0.7 percent and 0.9 percent, respectively .With our best-in-course infrastructure MFL is way better in a position to support Singapore's initiative to implement mass metering program for bunker and also to provide conformity assessment solutions of MFM locally. Through the R&D lab with NMC, local businesses like MFL can easily contribute towards enhancing the calibration services value chain. .

Affitech, Cancer Analysis Technology sign deal to advance therapeutic antibodies Cancer Study Technology, the business arm of Cancer Research UK, has signed a license agreement to grant antibody medicines organization, Affitech A/S, , exclusive privileges to a CRT patent software and relevant understand how to develop and use therapeutic antibodies that recognise and block the function of CCR4, a protein found on certain tumours – including early and later stage cervical cancer and oesophageal cancer.